WFA
AKRO

Wipfli Financial Advisors’s Akero Therapeutics AKRO Stock Holding History

Wipfli Financial Advisors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$10K Buy
+287
New +$4.39K ﹤0.01% 1829

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YCM
Yiheng Capital Management San Francisco, California $231M AUM 29.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wipfli Financial Advisors's AKRO Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Akero Therapeutics (AKRO) in Q3 2022: 287 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #1829 among its holdings.

146 funds tracked by Wall St. Rank hold AKRO as of Q3 2022.

  • Wipfli Financial Advisors held 287 shares of Akero Therapeutics worth $10K as of Q3 2022.
  • Akero Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
  • Akero Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1829 holding.
  • 146 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.